Molecular Neurobiology
June 4, 2025
Naser-Aldin Lashgari, Mahla Khalaji, Pouria Rana et al.
7 citations
Neurological and psychiatric disorders are considered one of the major problems of today's societies and cause many individual and social problems. Current treatments are effective, but due to their burdens, there is always an effort to introduce novel treatments. Psychedelics, a diverse group of psychoactive compounds, including LSD, psilocybin, DMT, MDMA, and ketamine, have shown potential in...
Naunyn-Schmiedeberg's archives of pharmacology
April 15, 2025
Arya Afrooghe, Elham Ahmadi, Ali Lesani et al.
We aimed to investigate whether psilocin, the bioactive metabolite of the well-known psychedelic, psilocybin, may have antipruritic effects in mice by interfering with the kynurenine pathway and interacting with 5-HT2A receptors. Eight mice were randomly assigned to each of the study groups receiving either normal saline, compound 48/80, psilocin (0.3, 1, and 3 mg/kg), or psilocin (1 mg/kg) +...
Pharmacology Research & Perspectives
February 25, 2025
Mohammad Balabandian, Mohammad Amin Manavi, Ali Lesani et al.
4 citations
ABSTRACT Epilepsy, a chronic neurological disorder affecting around 65 million people globally, is characterized by recurrent, unprovoked epileptic seizures. Psilocin, the active metabolite of psilocybin, a well‐known psychedelic compound, has recently gained attention for its potential antidepressant and anxiolytic properties. This study aims to investigate the anticonvulsant effects of...